Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China.
Faculty of Pharmacy, University of Sindh, Jamshoro-76080, Sindh, Pakistan.
J Pharm Pharmacol. 2024 Nov 4;76(11):1393-1403. doi: 10.1093/jpp/rgae108.
This study investigates the dual role of ALKBH5, an eraser enzyme, in colorectal cancer (CRC), focusing on how N6-methyladenosine (m6A) mutations influence CRC development and progression.
We reviewed various studies that highlighted the role of ALKBH5 in colorectal cancer (CRC). This includes the impact of ALKBH5 on tumor cell behavior including immune system interactions, invasion, and proliferation in CRC. We also looked into how ALKBH5 acts as a tumor suppressor under different conditions analyzed clinical data to assess the impact of ALKBH5 expression on outcomes in colorectal cancer patients.
In CRC, ALKBH5 plays a dual role. In certain situations, it inhibits the progression of the tumor, but in other circumstances, it promotes tumor growth and immunosuppression. The interaction with RABA5 plays a role in the development of CRC. Having elevated levels of ALKBH5 has been associated with unfavorable patient outcomes, such as reduced survival rates and more advanced cancer stages. Various factors, including tumor differentiation, TNM stages, and carcinoembryonic antigen (CEA) levels, be linked to ALKBH5 expression.
ALKBH5 plays a complicated and situation-specific role in colorectal cancer (CRC). Targeting ALKBH5 could result in novel therapy options that balance its tumor-promoting and tumor-fighting properties in CRC. Further research into m6A alterations and ALKBH5 could enhance CRC treatment approaches and patient outcomes.
本研究探讨了去甲基化酶 ALKBH5 在结直肠癌（CRC）中的双重作用，重点研究 N6-甲基腺苷（m6A）突变如何影响 CRC 的发生和发展。
我们回顾了各种强调 ALKBH5 在结直肠癌（CRC）中作用的研究。这包括 ALKBH5 对肿瘤细胞行为的影响，包括 CRC 中免疫系统相互作用、侵袭和增殖。我们还研究了 ALKBH5 在不同条件下如何作为肿瘤抑制因子发挥作用，分析了临床数据以评估 ALKBH5 表达对结直肠癌患者结局的影响。
在 CRC 中，ALKBH5 发挥双重作用。在某些情况下，它抑制肿瘤的进展，但在其他情况下，它促进肿瘤生长和免疫抑制。与 RABA5 的相互作用在 CRC 的发展中起作用。ALKBH5 水平升高与患者预后不良相关，例如生存率降低和癌症分期更晚。各种因素，包括肿瘤分化、TNM 分期和癌胚抗原（CEA）水平，与 ALKBH5 表达相关。
ALKBH5 在结直肠癌（CRC）中发挥复杂且特定于情况的作用。靶向 ALKBH5 可能会产生新的治疗选择，平衡其在 CRC 中的促肿瘤和抗肿瘤特性。进一步研究 m6A 改变和 ALKBH5 可以增强 CRC 的治疗方法和患者结局。
